## Edgar Filing: BELLICUM PHARMACEUTICALS, INC - Form 4

BELLICUM PHARMACEUTICALS, INC Form 4 February 26, 2015 OMB APPROVAL FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION OMB 3235-0287 Washington, D.C. 20549 Number: Check this box January 31, Expires: if no longer 2005 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF subject to Estimated average **SECURITIES** Section 16. burden hours per Form 4 or response... 0.5 Form 5 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, obligations Section 17(a) of the Public Utility Holding Company Act of 1935 or Section may continue. 30(h) of the Investment Company Act of 1940 See Instruction 1(b). (Print or Type Responses) 1. Name and Address of Reporting Person \* 5. Relationship of Reporting Person(s) to 2. Issuer Name and Ticker or Trading Farrell Thomas J. Issuer Symbol BELLICUM (Check all applicable) PHARMACEUTICALS, INC [BLCM] \_X\_ Director 10% Owner X\_Officer (give title Other (specify (Last) (First) (Middle) 3. Date of Earliest Transaction below) below) (Month/Day/Year) President and CEO C/O BELLICUM 02/24/2015 PHARMACEUTICALS, INC., 2130 W. HOLCOMBE BLVD., STE. 800 (Street) 4. If Amendment, Date Original 6. Individual or Joint/Group Filing(Check Filed(Month/Day/Year) Applicable Line) \_X\_ Form filed by One Reporting Person Form filed by More than One Reporting HOUSTON, TX 77030 Person (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of 2. Transaction Date 2A. Deemed 3. 4. Securities 5. Amount of 6. Ownership 7. Nature of TransactionAcquired (A) or Indirect Security (Month/Day/Year) Execution Date, if Securities Form: Direct (Instr. 3) Code Disposed of (D) Beneficially (D) or Indirect Beneficial any (Month/Day/Year) (Instr. 8) (Instr. 3, 4 and 5) Owned Ownership **(I)** Following (Instr. 4) (Instr. 4) Reported (A) Transaction(s) or (Instr. 3 and 4) Code V Amount (D) Price Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

number.

displays a currently valid OMB control

| 1. Title of<br>Derivative<br>Security<br>(Instr. 3) | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction Date<br>(Month/Day/Year) | 3A. Deemed<br>Execution Date, if<br>any<br>(Month/Day/Year) | 4.<br>Transacti<br>Code<br>(Instr. 8) | 5. Number of<br>orDerivative<br>Securities<br>Acquired (A) or<br>Disposed of (D)<br>(Instr. 3, 4, and<br>5) |    | 6. Date Exer<br>Expiration D<br>(Month/Day/ | ate                | 7. Title and A<br>Underlying S<br>(Instr. 3 and | Securities                       |
|-----------------------------------------------------|-----------------------------------------------------------------------|-----------------------------------------|-------------------------------------------------------------|---------------------------------------|-------------------------------------------------------------------------------------------------------------|----|---------------------------------------------|--------------------|-------------------------------------------------|----------------------------------|
|                                                     |                                                                       |                                         |                                                             | Code V                                | (A) (I                                                                                                      | D) | Date<br>Exercisable                         | Expiration<br>Date | Title                                           | Amount or<br>Number of<br>Shares |
| Stock<br>Option<br>(right to<br>buy)                | \$ 23.47                                                              | 02/24/2015                              |                                                             | A                                     | 160,000                                                                                                     |    | <u>(1)</u>                                  | 02/23/2025         | Common<br>Stock                                 | 160,000                          |

## Edgar Filing: BELLICUM PHARMACEUTICALS, INC - Form 4

## **Reporting Owners**

| Reporting Owner Name / Address                                                      |            | Relationships |                   |         |       |  |  |  |  |
|-------------------------------------------------------------------------------------|------------|---------------|-------------------|---------|-------|--|--|--|--|
|                                                                                     |            | Director      | 10% Owner         | Officer | Other |  |  |  |  |
| Farrell Thomas J.<br>C/O BELLICUM PHARM<br>2130 W. HOLCOMBE BL<br>HOUSTON, TX 77030 | Х          |               | President and CEO |         |       |  |  |  |  |
| Signatures                                                                          |            |               |                   |         |       |  |  |  |  |
| /s/ Thomas J.<br>Farrell                                                            | 02/26/2015 |               |                   |         |       |  |  |  |  |
| **Signature of                                                                      | Date       |               |                   |         |       |  |  |  |  |

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1)  $\frac{25\%}{\text{stock option vest and become exercisable on February 24, 2016, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.}$

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Person